SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced presentations at two upcoming scientific and medical conferences.
Keystone Symposia: Chromatin Architecture in Development and Human Health
Poster Title: Discovery and engineering of hypercompact transcriptional modulators for robust and durable target gene activation
Date & Time: Monday, March 13, 7:30 p.m. PT
Poster Number: 1507 (Session 1)
Location: Fairmont Empress Victoria Conference Center, British Columbia, Canada
MDA (Muscular Dystrophy Association) Clinical & Scientific Conference
Oral Presentation Title: EPI-321, a Potential Cure for FSHD
Date & Time: Wednesday, March 22, 10:15 a.m. CT
Location: Hilton Anatole, Dallas, Texas
About Epic Bio
Epic Bio is a leading epigenome engineering company, leveraging the power of CRISPR without cutting DNA. The company is using its proprietary Gene Expression Modulation System (GEMS) to develop therapies. Through the company’s library of the most compact Cas DNA-binding proteins to work on human cells, the company is developing in vivo therapies with delivery via a single AAV vector. Epic Bio has an initial focus on Facioscapulohumeral Muscular Dystrophy (FSHD) and is conducting additional research to address Antitrypsin Deficiency (A1AD), Heterozygous Familial Hypocholesterolemia (HeFH), as well as other indications. The company is financially backed by Horizons Ventures and other leading investors. Visit www.epic-bio.com for more information or follow us on Twitter and LinkedIn.
Contacts
Investor Contact
Shawn M. Cox
Epic Bio
Manager, Investor Relations, Corporate Communications
Media Contact
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783
